Related Experiment Video
Updated: Aug 6, 2026
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Chronic lymphocytic leukemic patients, resistant to chemotherapy
1Research Service, VA Hospital, Elmhurst, IL 60126.
Medical Hypotheses
|August 1, 1988
Summary
Many chronic lymphocytic leukemia (CLL) patients resist intensive chemotherapy, even in early stages. This highlights patient heterogeneity and the need for new therapies and diagnostic tests for non-responders.
Area of Science:
- Oncology
- Hematology
- Clinical Research
Background:
- Chronic lymphocytic leukemia (CLL) is a heterogeneous cancer.
- Chemotherapy is a standard treatment for advanced CLL.
- Treatment resistance is a significant clinical challenge.
Purpose of the Study:
- To investigate treatment response rates in advanced chronic lymphocytic leukemia (CLL).
- To identify factors associated with chemotherapy resistance in CLL patients.
- To support the need for novel therapeutic strategies and diagnostic tools for CLL.
Main Methods:
- Analysis of data from four studies involving intensive chemotherapy in advanced CLL patients.
- Evaluation of therapy response rates.
- Assessment of radioresistant lymphocytes in vitro as a potential predictor of resistance.
Main Results:
- Approximately 50% of advanced CLL patients did not respond to intensive chemotherapy.
- Therapy resistance was observed in 12% of early-stage CLL patients.
- 19 CLL patients with pre-therapy in vitro radioresistant lymphocytes also showed resistance.
Conclusions:
- Findings support the hypothesis that CLL is a heterogeneous disease.
- There is a critical need for new therapeutic approaches for non-responders.
- Development of in vitro or in vivo tests to diagnose non-responders is essential for personalized treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...